Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

POZEN welcomes Dr Seth Rudnick on board

This article was originally published in Scrip

Executive Summary

POZEN has elected Dr Seth Rudnick, a venture partner at Canaan Partners and clinical adjunct professor of medicine at the University of North Carolina, Chapel Hill, to its board of directors. Dr Rudnick has led many drug discovery and development projects throughout his career, which spans R&D, clinical trials analysis and biotechnology. He was previously CEO and chairman of Cyto Therapeutics, and has also worked for the Ortho Biotech division of Johnson & Johnson.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC013864

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel